Comparative effectiveness of tenofovir in treatment-näive HIV-infected patients: Systematic review and meta-analysis

HIV Clinical Trials

Volumn 16, Issue 5, 2015, Pages 178-189

  Hemkens, Lars G ^a   Ewald, Hannah ^a   Santini Oliveira, Marilia ^a,b   Bühler, Julian Emanuel ^a   Vuichard, Danielle ^c   Schandelmaier, Stefan ^a   Stöckle, Marcel ^c   Briel, Matthias ^a,d,e   Bucher, Heiner C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Funda??o Oswaldo Cruz   (Brazil)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antiretroviral na ve; HIV; Meta analysis; Tenofovir

Indexed keywords

ABACAVIR; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LIPID;

ARTICLE; BODY FAT; BONE DENSITY; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW; TREATMENT FAILURE; BLOOD; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84956872509     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1179/1945577115Y.0000000004     Document Type: Article

References (58)

1. European AIDS Clinical Society (EACS). EACS Guidelines Version 7. 2014. http://www.eacsociety.org/Portals/0/140601-EACS%20EN7.02.pdf. Accessed December 08, 2014.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.: Department of Health and Human Services; 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed Decmber 08, 2014.
3. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):1547-1556.
4. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med. 2011;154(7):445-456.
5. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
6. Cruciani M, Mengoli C, Malena M, Serpelloni G, Parisi SG, Moyle G, et al. Virological efficacy of abacavir: systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(12):3169-3180.
7. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
8. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012;12:234.
9. HIV drug therapy in the Americas congress 13-15 January 2013, São Paulo Brazil. J Int AIDS Soc. 2013;16(Suppl 1):18720.
10. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June-03 July 2013. Kuala-Lumpur, Malaysia, 2013.
11. 14th European AIDS Conference, 16-19 October 2013. Brussels, Belgium, 2013.
12. 11th international congress on drug therapy in HIV infection 11-15 November 2012, Glasgow UK. J Int AIDS Soc. 2012;15(Suppl 4):18060-18301.
13. XIX international AIDS conference 22-27 July 2012, Washington DC USA. J Int AIDS Soc. 2012;15 (Suppl 3).
14. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ. 2009;339:b3244.
15. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol. 2005;34(1):79-87.
16. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. www.cochrane-handbook.org.
17. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826.
18. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290.
19. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48(4):1062-1069.
20. Menezes CN, Crowther NJ, Duarte R, Van Amsterdam D, Evans D, Dickens C, et al. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and lowdose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014;15(1):3-12.
21. Menezes CN, Duarte R, Dickens C, Dix-Peek T, Van Amsterdam D, John MA, et al. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013;14(4):217-225.
22. Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, et al. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012;17(8):1521-1531.
23. Torti C, Cologni G, Quiros-Roldan E, Antinori A, Orani A, Tirelli V, et al. Lopinavir/r+zidovudine+lamivudine versus efavirenz+tenofovir+lamivudine as a first-line HAART: a pilot RCT (the Si. S. Ther. trial). 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007. Abstract no. CDB2462007.
24. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914-916.
25. Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, et al. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med. 2013;52(7):735-744.
26. Bedimo RJ, Drechsler H, Jain M, Cutrell J, Zhang S, Li X, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One. 2014;9(8):e106221.
27. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825-831.
28. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26(3):285-293.
29. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373-1381.
30. Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, Veloso VG, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med. 2010;11(9):554-564.
31. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofoviremtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49(10):1591-1601.
32. Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, et al. The effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2015;69(4):413-421.
33. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25(10):1289-1298.
34. Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis. 2015;61(3):445-452.
35. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336(7658):1413-1415.
36. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
37. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383(9913):267-276.
38. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191-1201.
39. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230-2240.
40. McComsey G, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG study A5224s. Clin Infect Dis. 2011;53(2):185-196.
41. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801.
42. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviralnaive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49-57.
43. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963-972.
44. Gallant JE, Staszewski S, Pozniak AL, De Jesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
45. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20(4):743-746.
46. Gallant JE, De Jesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
47. Pozniak AL, Gallant JE, De Jesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535-540.
48. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74-78.
49. Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, et al. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr. 2013;62(2):164-170.
50. Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, et al. Once-daily maraviroc in combination with ritonavir-boosted atazanavir in treatment-naive patients infected with CCR5-tropic HIV-1(study A4001078):96-week results. Paper presented at: J Int AIDS Soc. Conference: 19th International AIDS Conference Washington, DC United States. [Conference Start: 20120722 Conference End: 20120727. Conference Publication: (var.pagings), 15, pp 52-53, 2012. Date of Publication: 24 Oct. 2012].
51. Pinola M, Lazzarin A, Antinori A, Carosi G, Giovanni DP, Moroni M. Lopinavir/ritonavir + tenofovir dual therapy versus lopinavir/ritonavir-based triple therapy in HIV-infected antiretroviral naive subjects: the kalead study. J Antivir Antiretrovir. 2010;2(4):056-062.
52. Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-Week results from a randomized trial. AIDS. 2005;19(11):1183-1188.
53. Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006;11(1):73-78.
54. Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1:96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384(9958):1942-1951.
55. Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, et al. Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI-sparing regimen for HIV-infected naive patients: 48-weeks final results. J Int AIDS Soc. 2012;15(6):18232.
56. Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results. HIV Clin Trials. 2011;12(5):255-267.
57. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Human Retroviruses. 2013;29(2):256-265.
58. Torti C, Quiros-Roldan E, Regazzi M, Antinori A, Patroni A, Villani P, et al. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. 2005;10(4):505-513.